Addex Therapeutics Ltd
Addex Therapeutics Ltd (ADXN) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
adxn · stock forecast · 1 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 1 Wall Street analysts in the past 3 months
Buy
1 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$30.00
Consensus
$30.00
+411.9% upside
Low
$30.00
Median: $30 · Last Close: $5.86
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $5.65 | ↓ 3.59% |
1-day model range: $5.57–$5.73. Peak: $5.73 (-3.59%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -43.3% |
| 2028 | — | -55.5% |
| 2029 | — | -60.4% |
| 2030 | — | -62.5% |
| 2031 | — | -63.5% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · ADXN · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-07-31 | HC Wainwright & Co. | Upgrade ↑ | Neutral→Buy |
| 2022-06-22 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2022-05-30 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2022-02-10 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Addex Therapeutics Ltd (ADXN) stock. Of the recent 4 rating actions, 1 were upgrades and 1 were downgrades. 1 analysts currently cover ADXN.
Analyst Recommendation Trends
ADXN analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↓ 26.7% YoY
Revenue Next Year
$1M
↓ 5.2% YoY
EPS This Year
$-15.86
EPS Next Year
$-7.92
↓ 50.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast ADXN EPS of $-15.86 for the current fiscal year, based on estimates from 1 analysts. The ADXN revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ADXN stock forecast is supported by two independent data sources: analyst consensus ratings from 1 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ADXN price target is $30.00 (+411.9% upside), with an analyst consensus of Buy.
The ADXN short-term stock prediction for tomorrow is $5.65 (-3.59%). The ADXN stock prediction for 2030 projects a range of $2–$2.
Addex Therapeutics Ltd trades on NASDAQ under the ticker ADXN. The ADXN stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
ADXN forecast · 8 questionsAccording to 1 Wall Street analysts, the average 12-month ADXN price target is $30.00, with a high forecast of $30.00 and a low of $30.00. The median price target is shown in the chart above when available. This implies +411.9% potential upside from the current price of $5.86.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.